Uveitis, Posterior Clinical Trial
Official title:
Proof of Concept Study of the Effectiveness of Ozurdex in Lieu of Oral Corticosteroids for the Control of Active Intermediate and Posterior Uveitis Requiring Immunosuppressive Drug Therapy
The main purpose of this study is to evaluate whether or not the dexamethasone pellet
(Ozurdex®, Allergan, Irvine, CA) can replace oral corticosteroid (e.g. prednisone) in the
treatment of active sight-threatening, noninfectious intermediate and/or posterior uveitis in
which immunosuppressive drug therapy is indicated.
Uveitis is an inflammation inside the eye. Uveitis can decrease patients' vision if it is not
treated.
The dexamethasone pellet is an implant filled with a corticosteroid medicine. This therapy is
approved by the Food and Drug Administration (FDA) for the treatment of intermediate and/or
posterior uveitis.
In this study investigators want to see if using the implant together with systemic
immunosuppressive drug therapy can result in lower ocular side effect profile but is
effective enough to replace the use of high-dose systemic corticosteroids in the treatment of
active intermediate and/or posterior uveitis. Knowing the effectiveness and safety of these
treatments is important because the kinds of uveitis being studied usually need to be treated
for many years. This information may help researchers understand uveitis better and may
suggest ways of improving treatment.
Adult patients with intermediate and/or posterior uveitis for which immunosuppressive drug
therapy with high-dose corticosteroid is planned may join.
Objectives: This is a single arm study evaluating whether or not the dexamethasone pellet
(Ozurdex®, Allergan, Irvine, CA) can replace oral corticosteroid (e.g. prednisone) in the
treatment of active sight-threatening, noninfectious intermediate or posterior uveitis in
which immunosuppressive drug therapy is indicated.
Background: Intermediate and posterior uveitis are thought to be severe intraocular
inflammation that may lead to permanent visual loss. It is estimated that these forms of
uveitis comprise the fifth or sixth leading cause of blindness and tend to affect working
class age patients, thus causing loss of work hours and diminished productivity and quality
of life. Because the posterior segment of the eye is not adequately treated by corticosteroid
drops often systemic drug therapy is used including oral corticosteroids or prednisone.
Prednisone can have a myriad of side effects in approximately one-quarter to one-third of
cases treated in tertiary care centers such as ours, additional medications such as
immunosuppressive drugs are required to control the disease and/or to allow for appropriate
tapering of oral prednisone to subsequent levels that have a low side effect profile when
delivered over a long period of time. Typically, chronic prednisone therapy in doses of 7.5
mg daily or less are thought to have a low enough side effect profile to be amenable to
long-term therapy. However frequently immunosuppressive drugs are required to get the dosing
to this level. There are occasions when patients are intolerant of any dose of oral
corticosteroids or are intolerant of the higher doses of oral corticosteroids (30 - 60 mg
daily) and therefore this treatment modality is avoided due to prednisone's attendant side
effects. Although periocular and intravitreal corticosteroids injections may be performed,
with these modalities the standard of care is to wait until the disease reactivates before
instituting such therapy and therefore a chronic suppressive dose is not obtained. The
fluocinolone acetonide implant (Retisert®, Bausch and Lomb, Tampa, FL) is FDA-approved for
the treatment of intermediate and posterior uveitis and it is equally effective in
controlling uveitis as high-dose oral corticosteroids but avoids the systemic side effects
associated with the use of high doses of oral corticosteroids. However, this form of local
therapy has high rates of ocular side effects, including ocular hypertension causing glaucoma
and/or requiring glaucoma surgery and cataracts. Furthermore, every two and half to three
years the implant is exhausted of corticosteroid and therefore repeat surgical insertion of
another implant may be required. A useful potential therapy for the treatment of these
patients would be a shorter-acting local corticosteroid that could be delivered in
conjunction with systemic immunosuppressive drug therapy that would have a lower ocular side
effect profile but still would be effective enough to replace the use of high-dose systemic
corticosteroids in the treatment of active intermediate or posterior uveitis. It is possible
that the dexamethasone pellet could fill this unique role in the treatment of uveitis.
Investigators propose this study to evaluate dexamethasone pellet for this specific use among
patients with active intermediate and posterior uveitis.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00570479 -
Prophylactic Anecortave Acetate in Patients With a Retisert Implant
|
Phase 1 | |
Recruiting |
NCT05486468 -
The Use of Two YUTIQ Versus Sham for Treatment of Chronic Non Infectious Intraocular Inflammation Affecting the Posterior Segment
|
Phase 3 | |
Terminated |
NCT03656692 -
Safety and Effectiveness of Acthar Gel for Inflammation of the Eye's Uvea (Middle Layer)
|
Phase 4 | |
Completed |
NCT02255032 -
Suprachoroidal Injection of Triamcinolone Acetonide in Subjects With Macular Edema Following Non-Infectious Uveitis
|
Phase 2 | |
Completed |
NCT00035906 -
Research Study in Patients With Persistent Macular Edema
|
Phase 2 | |
Recruiting |
NCT05101928 -
Ozurdex Monotherapy Trial
|
Phase 4 | |
Terminated |
NCT05070728 -
Safety and Efficacy of an Injectable Fluocinolone Acetonide Intravitreal Insert (FAI)
|
Phase 3 | |
Completed |
NCT02595398 -
Suprachoroidal Injection of CLS-TA in Subjects With Macular Edema Associated With Non-infectious Uveitis
|
Phase 3 | |
Recruiting |
NCT03066869 -
Efficacy and Safety of H.P. ACTHAR GEL in Adults With Retinal Vasculitis
|
Phase 4 | |
Completed |
NCT01539577 -
A Long-Term Safety Study of OZURDEX® in Clinical Practice
|
N/A | |
Recruiting |
NCT05322070 -
Fluocinolone Acetonide Intravitreal Implant 0.18 mg in the Treatment of Chronic Non-Infectious Posterior Segment Uveitis
|
Phase 4 | |
Recruiting |
NCT06085079 -
Ixekizumab for the Management of Refractory Non-Infectious Uveitis: A Proof-of-Concept Study
|
Phase 4 | |
Completed |
NCT03145025 -
Corneal Endothelial Cell Density in Eyes Treated With a Fluocinolone Acetonide Intravitreal Implant
|
||
Withdrawn |
NCT01905124 -
Safety &Efficacy of CF101 to Subjects With Uveitis
|
Phase 2 | |
Completed |
NCT03598452 -
High-dose Intravitreal Injection of Ganciclovir for the Treatment of CMVR in HIV-negative Patients
|
N/A | |
Completed |
NCT00404612 -
A Study of LX211 in Active Sight Threatening, Non-infectious Intermediate-, Anterior and Intermediate-, Posterior-, or Pan-Uveitis
|
Phase 3 | |
Completed |
NCT00404742 -
A Study of LX211 in Clinically Quiescent Non-infectious Intermediate, Anterior and Intermediate, Posterior or Pan-Uveitis
|
Phase 3 | |
Completed |
NCT02952001 -
MAGNOLIA: Extension Study of Patients With Non-infectious Uveitis Who Participated in CLS1001-301
|
||
Not yet recruiting |
NCT06431373 -
A Study of Brepocitinib in Adults With Active, Non-Infectious, Non-Anterior Uveitis
|
Phase 3 | |
Completed |
NCT03097315 -
Suprachoroidal Injection of CLS-TA in Patients With Non-infectious Uveitis
|
Phase 3 |